Navigation Links
QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
Date:10/25/2012

HILDEN, Germany, October 25, 2012 /PRNewswire/ --

  • QIAGEN and Bayer HealthCare signed collaboration agreement aimed at advancing both companies positions in personalized medicine
  • The programs pair QIAGEN companion diagnostic solutions with innovative targeted therapies for patients with solid tumors developed by Bayer HealthCare
  • Agreement provides framework for further collaboration projects

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) and Bayer HealthCare today announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular information from each patient's tumor genome to guide treatment decisions with medications for cancers or other diseases. The parties will also collaborate on the development of novel technologies for patient profiling which may result in innovative research-use-only products for exploratory and translational medicine. Financial details were not disclosed.

The targeted companion diagnostics will be designed to run on the QIAsymphony family of automated instruments, which is transforming laboratory workflows and helping disseminate standardized, regulator-approved diagnostics.

"We are very pleased to partner with Bayer HealthCare in developing companion diagnostics to improve life for cancer patients. As healthcare providers increasingly select the right drugs based on each individual's genomic information, the treatment of cancer is undergoing a revolution," said Dr. Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and Member of the Executive Committee of QIAGEN. "The first collaborations for Bayer HealthCare and QIAGEN include companion diagnostics ba
'/>"/>

SOURCE Qiagen N V
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
2. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
3. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
4. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
5. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
6. Bayer Advanced(TM) Sets Sights on New Partnerships in 2013
7. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
8. AspenBio to Present at 2012 Aegis Healthcare Conference
9. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
10. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
11. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 20, 2014 One of the ... is an inadequate vascular supply. Nutrient and gas ... tissues is critical for successful regeneration and integration ... mitigate deficiencies in vascularization and promote angiogenesis in ... optimizing scaffold design and architecture, and enhancing scaffolds ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Shimadzu ... chromatography systems, Prominence-i and Nexera-i, adding to the ... Combining excellent functionality, an intuitive operating environment, and ... a more efficient workflow for conventional to ultra-high-speed ... innovative, intuitive and intelligent design so users can ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
(Date:8/19/2014)... 19, 2014 A Geisinger researcher on a ... a Centers for Disease Control and Prevention (CDC) award ... health concern. Joseph Boscarino , Ph.D. ... a team of researchers nominated for the Centers for ... Award for Data Methods and Study Design. ...
Breaking Biology Technology:Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... Advanced Instruments, Inc., of,Norwood, Massachusetts, announced today ... D & F Control Systems, Inc., of Dublin, ... D & F Control Systems manufactures and ... laboratories around the world. Their,patented preservatives ensure component ...
... Operations Appointed -, CLINTON, N.J., Oct. 2 ... Michael Kennedy as Senior Vice President,Engineering and Operations. ... technology strategy and development., "Michael,s extensive experience ... as we continue to advance our pharmaceutical,pipeline through ...
... the largest non-state-owned producers of ... plasma-based product in China, ... (OTC Bulletin Board: CBPO) ("China Biologic" or the,"Company"), one of ... ("PRC"), today announced that on September 26,2008, the Company has ...
Cached Biology Technology:Advanced Instruments Acquires D & F Control Systems Inc. 2Ikaria Strengthens Executive Leadership Team 2China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 2China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 3China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 4China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 5
(Date:8/19/2014)... have identified a biomarker strongly associated with basal-like ... resistant to many types of chemotherapy. The biomarker, ... for new therapeutics designed to treat this often ... taken from The Cancer Genome Atlas, molecular biologists ... powerful computational and bioinformatics techniques to detect patterns ...
(Date:8/19/2014)... ancestors of today,s crocodiles colonised the seas during warm ... a new Anglo-French study which establishes a link between ... over a period of more than 140 million years. ... from the Universit de Lyon, France and formerly from ... in Nature Communications ., Today, crocodiles are ,cold-blooded, ...
(Date:8/19/2014)... fizzy soda knows that bubbles can throw tiny particles ... industrial applications, Princeton researchers have demonstrated that the bursting ... well. , "It is well known that bursting bubbles ... to discover that when we covered the water with ... the water," said Howard Stone, the Donald R. Dixon ...
Breaking Biology News(10 mins):Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3Evolution of marine crocodilians constrained by ocean temperatures 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... wringing every drop of energy from as many photons ... chemistry, materials science and electronic engineering researchers on a ... but existing techniques are now running up against limits ... Now, researchers from the University of Pennsylvania and Drexel ...
... BURLINGTON, Mass. , Nov. 12, 2013  Decision Resources, ... for pharmaceutical and healthcare issues, finds that while most ... play a critical role in pharmaceutical development of chronic ... outside of oncology is building. The Strategic Insights report ...
... more meat, milk and eggs in their diets. Increased ... livestock production and massive environmental consequences at local, regional ... Treatment and Management, draws from Danish expertise and spotlights ... work and ensure the use of animal manure,s stinking ...
Cached Biology News:Penn and Drexel team demonstrates new paradigm for solar cell construction 2Penn and Drexel team demonstrates new paradigm for solar cell construction 3Penn and Drexel team demonstrates new paradigm for solar cell construction 4Penn and Drexel team demonstrates new paradigm for solar cell construction 5Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing 2New textbook tackles the sustainable recycling of manure 2
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
Mouse monoclonal antibody raised against a partial recombinant KRT4. NCBI Entrez Gene ID = KRT4...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... PrecisION Ion Channel Cell Lines ,High Quality, ... channels are well known for having a ... and consequently have a key function in ... modulate ion channels have been investigated in ...
Biology Products: